Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders

Patent metadata

Field	Value
Publication number	US-11027015-B2
Application number	US-202016909578-A
Country	US
Kind code	B2
Filing date	Jun 23, 2020
Priority date	Aug 1, 2016
Publication date	Jun 8, 2021
Grant date	Jun 8, 2021

Abstract

The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. An isolated antibody, or antigen-binding fragment thereof, that binds to human MASP-3 comprising:
a heavy chain variable region comprising a HC-CDR1 set forth as SEQ ID NO:72 (SYGMS) a HC-CDR2 set forth as SEQ ID NO:74 (WINTYSGVPTYADDFKG); and a HC-CDR3 set forth as SEQ ID NO:76 (GGEAMDY); and a light chain variable region comprising a LC-CDR1 selected from the group consisting of SEQ ID NO:153 (KSSQSLLDSDGKTYLN), SEQ ID NO:261 (KSSQSLLDSEGKTYLN), SEQ ID NO:262 (KSSQSLLDSAGKTYLN) and SEQ ID NO:263 (KSSQSLLDSDAKTYLN); a LC-CDR2 set forth as SEQ ID NO:155 (LVSKLDS); and a LC-CDR3 set forth as SEQ ID NO:157 (WQGTHFPWT).

2. The isolated antibody, or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:261 (KSSQSLLDSEGKTYLN).

3. The isolated antibody, or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:262 (KSSQSLLDSAGKTYLN).

4. The isolated antibody, or antigen-binding fragment thereof of claim 1 , wherein the LC-CDR1 comprises SEQ ID NO:263 (KSSQSLLDSDAKTYLN).

5. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR1 comprises SEQ ID NO:72, the HC-CDR2 comprises SEQ ID NO:74, the HC-CDR3 comprises SEQ ID NO:76, the LC-CDR1 comprises SEQ ID NO:153, the LC-CDR2 comprises SEQ ID NO:155 and the LC-CDR3 comprises SEQ ID NO:157.

6. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the HC-CDR1 comprises SEQ ID NO:72, the HC-CDR2 comprises SEQ ID NO:74, the HC-CDR3 comprises SEQ ID NO:76, the LC-CDR1 comprises SEQ ID NO:263, the LC-CDR2 comprises SEQ ID NO:155 and the LC-CDR3 comprises SEQ ID NO:157.

7. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:28, SEQ ID NO:251 and SEQ ID NO:252.

8. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:253 and SEQ ID NO:279.

9. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is selected from the group consisting of a humanized antibody, a chimeric antibody, a murine antibody, and an antigen-binding fragment of any of the foregoing.

10. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or antigen binding fragment thereof is selected from the group consisting of a single chain antibody, an ScFv, a Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a univalent antibody lacking a hinge region and a whole antibody.

11. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody inhibits alternative pathway activation in mammalian blood.

12. A composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable excipient.

13. An isolated antibody or antigen-binding fragment thereof that binds to human MASP-3, comprising a heavy chain variable region selected from the group consisting of SEQ ID NO:28, SEQ ID NO:251 and SEQ ID NO:252 and a light chain variable region selected from the group consisting of SEQ ID NO:43, SEQ ID NO:253 and SEQ ID NO:279.

14. The isolated antibody or antigen-binding fragment thereof of claim 13 , wherein the heavy chain variable region comprises SEQ ID NO:28 and the light chain variable region comprises SEQ ID NO:43.

15. The isolated antibody or antigen-binding fragment thereof of claim 13 , wherein the heavy chain variable region comprises SEQ ID NO:251 or SEQ ID NO:252 and the light chain variable region comprises SEQ ID NO:253.

16. The isolated antibody or antigen-binding fragment thereof of claim 13 , wherein the heavy chain variable region comprises SEQ ID NO:251 or SEQ ID NO:252 and the light chain variable region comprises SEQ ID NO:279.

17. The isolated antibody of claim 13 , wherein the antibody is selected from the group consisting of a single chain antibody, an ScFv, a Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a univalent antibody lacking a hinge region and a whole antibody.

18. The isolated antibody or antigen-binding fragment thereof of claim 13 , wherein said antibody inhibits alternative pathway activation in mammalian blood.

19. A composition comprising the antibody or antigen-binding fragment of claim 13 and a pharmaceutically acceptable excipient.

Assignees

• Omeros Corp

Inventors

• Cummings W Jason
• Demopulos Gregory A
• Dudler Thomas
• Tjoelker Larry W
• Wood Christi L
• Yabuki Munehisa

Classifications

• H01F1/0054

  Coated nanoparticles, e.g. nanoparticles coated with organic surfactant · CPC title

• C12Y304/21104

  Mannan-binding lectin-associated serine protease-2 (3.4.21.104) · CPC title

• C12N9/6424

  Serine endopeptidases (3.4.21) · CPC title

• C09K11/7728

  containing europium · CPC title

• C09K11/77

  containing rare earth metals · CPC title